PE20081881A1 - Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos - Google Patents
Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usosInfo
- Publication number
- PE20081881A1 PE20081881A1 PE2008000464A PE2008000464A PE20081881A1 PE 20081881 A1 PE20081881 A1 PE 20081881A1 PE 2008000464 A PE2008000464 A PE 2008000464A PE 2008000464 A PE2008000464 A PE 2008000464A PE 20081881 A1 PE20081881 A1 PE 20081881A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- agents
- active ingredient
- hla class
- chemotherapic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN ANTICUERPO QUE RECONOCE HLA DE CLASE I COMO INGREDIENTE ACTIVO, EN COMBINACION CON UN AGENTE QUIMIOTERAPICO. EL ANTICUERPO ES DE BAJO PESO MOLECULAR. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE TUMOR HEMATOLOGICO RESISTENTE A AGENTES TERAPEUTICOS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007062339 | 2007-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081881A1 true PE20081881A1 (es) | 2009-02-18 |
Family
ID=39759531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000464A PE20081881A1 (es) | 2007-03-12 | 2008-03-12 | Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100092461A1 (es) |
EP (1) | EP2133093A1 (es) |
JP (1) | JPWO2008111597A1 (es) |
KR (1) | KR20090119992A (es) |
CN (1) | CN101687034A (es) |
AR (1) | AR066690A1 (es) |
AU (1) | AU2008225478A1 (es) |
BR (1) | BRPI0808731A2 (es) |
CA (1) | CA2680280A1 (es) |
CL (1) | CL2008000719A1 (es) |
IL (1) | IL200375A0 (es) |
MX (1) | MX2009009700A (es) |
PE (1) | PE20081881A1 (es) |
TW (1) | TW200846372A (es) |
WO (1) | WO2008111597A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003271175A1 (en) * | 2002-10-11 | 2004-05-04 | Masahiro Abe | Cell death-inducing agent |
CA2548929A1 (en) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducing agent |
WO2005100560A1 (ja) * | 2004-04-09 | 2005-10-27 | Chugai Seiyaku Kabushiki Kaisha | 細胞死誘導剤 |
EP1927367A4 (en) * | 2005-05-18 | 2009-08-12 | Univ Tokushima | NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY |
AU2006256041B2 (en) * | 2005-06-10 | 2012-03-29 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) * | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
CA2657385A1 (en) * | 2006-07-13 | 2008-01-17 | Naoki Kimura | Cell death inducer |
RS56773B1 (sr) * | 2012-01-13 | 2018-04-30 | Univ Wuerzburg J Maximilians | Dvojna bipartitna funkcionalna komplementacija izazvana antigenom |
UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
WO2021127305A1 (en) * | 2019-12-20 | 2021-06-24 | Virginia Commonwealth University | Methods and compositions for inducing apoptosis in cancer stem cells |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5077216A (en) * | 1988-07-06 | 1991-12-31 | The Trustees Of Dartmouth College | Monoclonal antibodies specific for a human mononculear phagocyte-specific antigen |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5223241A (en) * | 1990-10-01 | 1993-06-29 | The General Hospital Corporation | Method for early detection of allograft rejection |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
DE69232604T2 (de) * | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | Antikörperkonstrukte |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5837242A (en) * | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
SG55079A1 (en) * | 1992-12-11 | 1998-12-21 | Dow Chemical Co | Multivalent single chain antibodies |
US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
US5747654A (en) * | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
ZA946767B (en) * | 1993-09-03 | 1995-04-03 | Chugai Pharmaceutical Co Ltd | Monocional antibodies having property of causing apoptosis. |
AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
CA2195557C (en) * | 1994-08-12 | 2006-10-17 | Shui-On Leung | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
US6451523B1 (en) * | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
US5690935A (en) * | 1995-01-13 | 1997-11-25 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting TP-3/P80 |
MX9706538A (es) * | 1995-02-28 | 1997-11-29 | Procter & Gamble | Preparacion de productos de bebida no carbonatada que tienen estabilidad microbiana superior. |
EP0817794A1 (en) | 1995-03-31 | 1998-01-14 | Jakob Bohr | Method for protein folding |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP2258726A1 (en) * | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
CA2241564C (en) * | 1996-01-08 | 2013-09-03 | Genentech, Inc. | Wsx receptor and ligands |
FR2745008A1 (fr) * | 1996-02-20 | 1997-08-22 | Ass Pour Le Dev De La Rech En | Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre |
EP0903149A4 (en) * | 1996-03-06 | 2002-02-13 | Chugai Pharmaceutical Co Ltd | METHOD FOR SCREENING SUBSTANCES INDUCING APOPTOSIS |
EP0906119B1 (en) * | 1996-05-09 | 2006-02-01 | Pharma Pacific Pty. Ltd. | Stimulation of host defense mechanisms against cancer |
US6323000B2 (en) * | 1996-12-20 | 2001-11-27 | Clark A. Briggs | Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof |
US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
WO1999002567A2 (en) * | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
KR20010023866A (ko) * | 1997-09-11 | 2001-03-26 | 나가야마 오사무 | 아포토시스를 유기하는 모노클로날 항체 |
US7531643B2 (en) * | 1997-09-11 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
US5998593A (en) * | 1998-03-10 | 1999-12-07 | Abbott Laboratories | Fluorescent enzyme substrates |
US7081360B2 (en) * | 1998-07-28 | 2006-07-25 | Cadus Technologies, Inc. | Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties |
US7696325B2 (en) * | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US20040058393A1 (en) * | 2000-04-17 | 2004-03-25 | Naoshi Fukishima | Agonist antibodies |
CA2426621A1 (en) * | 2000-10-03 | 2003-04-01 | Banyu Pharmaceutical Co., Ltd. | Drug resistance-associated gene and use thereof |
US20040242847A1 (en) * | 2000-10-20 | 2004-12-02 | Naoshi Fukushima | Degraded agonist antibody |
US8034903B2 (en) * | 2000-10-20 | 2011-10-11 | Chugai Seiyaku Kabushiki Kaisha | Degraded TPO agonist antibody |
DK1456360T3 (en) * | 2001-04-19 | 2015-08-31 | Scripps Research Inst | Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs |
KR20050036852A (ko) * | 2001-10-15 | 2005-04-20 | 기린 비루 가부시키가이샤 | 항-hla-dr 항체 |
KR20050036875A (ko) * | 2001-10-15 | 2005-04-20 | 이뮤노메딕스, 인코오포레이티드 | 직접 표적형의 결합 단백질 |
EP3192528A1 (en) * | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
ATE482719T1 (de) * | 2002-02-21 | 2010-10-15 | Univ Duke | Behandlungsverfahren unter verwendung von anti- cd22-antikörpern |
US20050130224A1 (en) * | 2002-05-31 | 2005-06-16 | Celestar Lexico- Sciences, Inc. | Interaction predicting device |
US7098016B2 (en) * | 2002-06-14 | 2006-08-29 | Wisconsin Alumni Research Foundation | Ribonuclease zymogen design |
CA2487321A1 (en) * | 2002-06-17 | 2003-12-24 | The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services | Specificity grafting of a murine antibody onto a human framework |
US7115373B2 (en) * | 2002-06-27 | 2006-10-03 | Genox Research, Inc. | Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene |
AU2003271175A1 (en) | 2002-10-11 | 2004-05-04 | Masahiro Abe | Cell death-inducing agent |
JPWO2004037293A1 (ja) * | 2002-10-22 | 2006-02-23 | 大日本住友製薬株式会社 | 安定化組成物 |
JP2004279086A (ja) * | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
JPWO2004087763A1 (ja) * | 2003-03-31 | 2006-07-27 | 中外製薬株式会社 | Cd22に対する改変抗体およびその利用 |
ES2381841T3 (es) * | 2003-07-11 | 2012-06-01 | Oncotherapy Science, Inc. | Método para tratar el sarcoma sinovial |
CA2548929A1 (en) | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducing agent |
EP1710255A4 (en) * | 2003-12-12 | 2008-09-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR |
TW200530266A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Method of reinforcing antibody activity |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Dr5 항체 및 그의 용도 |
WO2005100560A1 (ja) | 2004-04-09 | 2005-10-27 | Chugai Seiyaku Kabushiki Kaisha | 細胞死誘導剤 |
JP4700970B2 (ja) | 2005-01-14 | 2011-06-15 | 鬼怒川ゴム工業株式会社 | ドアグラスランの取付構造 |
WO2006106903A1 (ja) * | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2構造異性体 |
EP1927367A4 (en) | 2005-05-18 | 2009-08-12 | Univ Tokushima | NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY |
AU2006256041B2 (en) * | 2005-06-10 | 2012-03-29 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
TW200718780A (en) * | 2005-06-10 | 2007-05-16 | Chugai Pharmaceutical Co Ltd | Sc(Fv)2 site-directed mutant |
US7827400B2 (en) * | 2005-07-28 | 2010-11-02 | The Boeing Company | Security certificate management |
CA2657385A1 (en) * | 2006-07-13 | 2008-01-17 | Naoki Kimura | Cell death inducer |
WO2008020586A1 (en) * | 2006-08-14 | 2008-02-21 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
-
2008
- 2008-03-11 CL CL200800719A patent/CL2008000719A1/es unknown
- 2008-03-12 CN CN200880015359A patent/CN101687034A/zh active Pending
- 2008-03-12 BR BRPI0808731-8A2A patent/BRPI0808731A2/pt not_active IP Right Cessation
- 2008-03-12 JP JP2009504061A patent/JPWO2008111597A1/ja not_active Withdrawn
- 2008-03-12 WO PCT/JP2008/054443 patent/WO2008111597A1/ja active Application Filing
- 2008-03-12 EP EP08721859A patent/EP2133093A1/en not_active Withdrawn
- 2008-03-12 TW TW097108682A patent/TW200846372A/zh unknown
- 2008-03-12 PE PE2008000464A patent/PE20081881A1/es not_active Application Discontinuation
- 2008-03-12 AU AU2008225478A patent/AU2008225478A1/en not_active Abandoned
- 2008-03-12 AR ARP080101014A patent/AR066690A1/es not_active Application Discontinuation
- 2008-03-12 MX MX2009009700A patent/MX2009009700A/es not_active Application Discontinuation
- 2008-03-12 CA CA002680280A patent/CA2680280A1/en not_active Abandoned
- 2008-03-12 US US12/530,670 patent/US20100092461A1/en not_active Abandoned
- 2008-03-12 KR KR1020097021153A patent/KR20090119992A/ko not_active Application Discontinuation
-
2009
- 2009-08-13 IL IL200375A patent/IL200375A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2009009700A (es) | 2009-10-07 |
WO2008111597A1 (ja) | 2008-09-18 |
IL200375A0 (en) | 2010-04-29 |
BRPI0808731A2 (pt) | 2013-08-06 |
TW200846372A (en) | 2008-12-01 |
AU2008225478A1 (en) | 2008-09-18 |
CN101687034A (zh) | 2010-03-31 |
KR20090119992A (ko) | 2009-11-23 |
CA2680280A1 (en) | 2008-09-18 |
JPWO2008111597A1 (ja) | 2010-06-24 |
CL2008000719A1 (es) | 2008-09-05 |
EP2133093A1 (en) | 2009-12-16 |
US20100092461A1 (en) | 2010-04-15 |
AR066690A1 (es) | 2009-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081881A1 (es) | Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos | |
CY1122417T1 (el) | Μεθοδοι και συνθεσεις για παρατεταμενη παροχη φαρμακων | |
CR20160271A (es) | Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco | |
CL2008001268A1 (es) | Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor. | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
CL2015001984A1 (es) | (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos. | |
GT201000008A (es) | Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico | |
UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
PE20151070A1 (es) | Inhibidores de la tirosina - quinasa de bruton | |
CR11455A (es) | Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades | |
CL2015002736A1 (es) | Composición farmacéutica de clorhidrato de s-ketamina. | |
CL2013003577A1 (es) | Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas. | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
BRPI0911384A8 (pt) | Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm) | |
CL2007001318A1 (es) | Uso de flibanserina,opcionalmente como base libre,sal hidrato o solvato de ella,para preparar un medicamento util en el tratamiento de trastornos de deseo sexual en mujeres. | |
BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
CL2011000214A1 (es) | Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona. | |
BR112015004515A2 (pt) | composição imunogênica | |
ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
CO6660486A2 (es) | Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
BRPI1011071B8 (pt) | uso de um heptapeptídeo para estimular a função genital, sexual ou reprodutiva em um mamífero |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |